2 hours ago • PR Newswire
EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics